BioVex to Present at 29th Annual JP Morgan Healthcare Conference

WOBURN, Mass.--(BUSINESS WIRE)-- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announces today that its CEO, Philip Astley-Sparke will present at the 29th Annual J.P Morgan Healthcare Conference in San Francisco on Wednesday 12th January at 4:00 PM PST.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, Mass. where it also has an operational commercial scale manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease. In addition to OncoVEX GM-CSF, the Company has a second development program, ImmunoVEX HSV2, a vaccine for genital herpes that is undergoing clinical testing in the United Kingdom.

About OncoVEX GM-CSF

OncoVEX GM-CSF is a first in class oncolytic vaccine which replicates selectively in tumors destroying cancer cells whist leaving surrounding healthy cells unharmed. OncoVEX GM-CSF is also intended to induce a powerful immune response to kill cancer cells throughout the body and to vaccinate against disease relapse. Both modes of action have been validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have become free of disease. BioVex believes OncoVEX GM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company is currently conducting a Phase 3 study in metastatic melanoma (the OPTiM study) following achieving an unprecedented proportion of durable complete remissions in a Phase 2 study using OncoVEX GM-CSF as a stand alone therapy. A second Phase 3 study in Head & Neck cancer commenced in December 2010. For further information, please go to www.biovex.com.



CONTACT:

BioVex Inc.
Philip Astley-Sparke, 781-376-4913
President & CEO
[email protected]
or
Shoreham Group LLC
Rebecca Skye Dietrich, 857-241-0795
Vice President
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.